Menu Search
Equities

Edwards Lifesciences Corp

EW:NYQ

Edwards Lifesciences Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)67.53
  • Today's Change0.300 / 0.45%
  • Shares traded9.59m
  • 1 Year change-7.42%
  • Beta1.1340
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 18-Sep-24
Select bar for recommendation details.
Recommendations18-Sep-24
Buy3
Outperform11
Hold17
Sell0
Strong Sell1

Share price forecast in USD

The 26 analysts offering 12 month price targets for Edwards Lifesciences Corp have a median target of 75.50, with a high estimate of 90.00 and a low estimate of 65.00. The median estimate represents a 11.80% increase from the last price of 67.53.
High33.3%90.00
Med11.8%75.50
Low-3.7%65.00

Earnings history & estimates in USD

On Jul 24, 2024, Edwards Lifesciences Corp reported 2nd quarter 2024 earnings of 0.70 per share. This result was in line with the consensus of the 26 analysts following the company and exceeded last year's 2nd quarter results by 6.06%.
The next earnings announcement is expected on Oct 23, 2024.
Average growth rate+1.76%
Edwards Lifesciences Corp reported annual 2023 earnings of 2.51 per share on Feb 06, 2024.
Average growth rate+8.11%
More ▼

Revenue history & estimates in USD

Edwards Lifesciences Corporation had 2nd quarter 2024 revenues of 1.63bn. This missed the 1.65bn consensus estimate of the 25 analysts following the company. This was 11.83% above the prior year's 2nd quarter results.
Average growth rate+1.67%
Edwards Lifesciences Corporation had revenues for the full year 2023 of 6.00bn. This was 11.56% above the prior year's results.
Average growth rate+8.65%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.